Doc's Guide -- Normalisation of insulin-like growth factor 1 (IGF-1) results in a significant decrease in cardiovascular (CV) risk in acromegalic patients, according to a study reported here at the 14th Congress of the European Neuroendocrine Association (ENEA).
